NantKwest Announces Closing of Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares

CULVER CITY, Calif.–(BUSINESS WIRE)–NantKwest, Inc. (formerly Conkwest, Inc.) (Nasdaq: NK), a clinical-stage immunotherapy company focused on harnessing the power of the innate immune system by using the natural killer cell to treat cancer, infectious diseases and inflammatory diseases, announced today the closing of its initial public offering of 9,531,200 shares of common stock at a price to the public of $25.00 per share, which included 1,243,200 shares sold pursuant to the exercise in ful


Print Friendly, PDF & Email

Share This

Share this post with your friends!